MX2020003243A - Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. - Google Patents

Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.

Info

Publication number
MX2020003243A
MX2020003243A MX2020003243A MX2020003243A MX2020003243A MX 2020003243 A MX2020003243 A MX 2020003243A MX 2020003243 A MX2020003243 A MX 2020003243A MX 2020003243 A MX2020003243 A MX 2020003243A MX 2020003243 A MX2020003243 A MX 2020003243A
Authority
MX
Mexico
Prior art keywords
heart failure
ejection fraction
methods
preserved ejection
treating heart
Prior art date
Application number
MX2020003243A
Other languages
English (en)
Inventor
Sophie Hallakou-Bozec
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of MX2020003243A publication Critical patent/MX2020003243A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para tratar o prevenir la insuficiencia cardíaca con fracción de eyección preservada (HFPEF), en el que el método comprende administrar a un paciente que tiene o está en riesgo de desarrollar HFPEF una cantidad terapéuticamente efectiva de imeglimina.
MX2020003243A 2017-10-02 2018-10-02 Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada. MX2020003243A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566668P 2017-10-02 2017-10-02
PCT/IB2018/057648 WO2019069230A1 (en) 2017-10-02 2018-10-02 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION

Publications (1)

Publication Number Publication Date
MX2020003243A true MX2020003243A (es) 2020-09-18

Family

ID=63963334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003243A MX2020003243A (es) 2017-10-02 2018-10-02 Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.

Country Status (12)

Country Link
US (1) US11617754B2 (es)
EP (1) EP3691650A1 (es)
JP (1) JP2020536121A (es)
KR (1) KR20200102982A (es)
CN (1) CN111163782A (es)
BR (1) BR112020006472A2 (es)
CA (1) CA3078163A1 (es)
IL (1) IL273723A (es)
MX (1) MX2020003243A (es)
TW (1) TW201924689A (es)
WO (1) WO2019069230A1 (es)
ZA (1) ZA202002292B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
SG11202007172YA (en) 2018-06-06 2020-08-28 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
CN115770062B (zh) * 2021-09-07 2025-10-10 深圳迈瑞生物医疗电子股份有限公司 一种超声波数据的处理方法、成像装置
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
KR101618198B1 (ko) 2008-05-23 2016-05-04 뽁셀 에스아에스 3,6-디히드로-1,3,5-트리아진 유도체의 제조방법
HUE028587T2 (en) 2008-07-29 2016-12-28 Poxel Method for separating enantiomeric components from enantiomeric mixtures by particle size controlled separation
BRPI0922650A2 (pt) 2008-12-12 2017-07-11 Poxel Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
SG171986A1 (en) 2008-12-12 2011-07-28 Merck Patent Gmbh Combination of insulin with triazine derivatives and its use for treating diabetes
JP5536869B2 (ja) 2009-03-26 2014-07-02 ポクセル・エスアーエス 優先晶出法を利用したジヒドロ−１，３，５トリアジンラセミ体のエナンチオマー分離のための方法
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
JP5707489B2 (ja) * 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ １型糖尿病の処置
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
PL2646422T3 (pl) 2010-12-01 2015-12-31 Poxel Rozdział enancjomerów pochodnych triazyny z zastosowaniem kwasu winowego
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US10285973B2 (en) 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
CN118903166A (zh) * 2016-03-16 2024-11-08 勃林格殷格翰国际有限公司 包含恩格列净的药物组合物及其用途
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
SG11202007172YA (en) 2018-06-06 2020-08-28 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease

Also Published As

Publication number Publication date
IL273723A (en) 2020-05-31
TW201924689A (zh) 2019-07-01
EP3691650A1 (en) 2020-08-12
KR20200102982A (ko) 2020-09-01
US20200316078A1 (en) 2020-10-08
US11617754B2 (en) 2023-04-04
JP2020536121A (ja) 2020-12-10
CN111163782A (zh) 2020-05-15
BR112020006472A2 (pt) 2020-10-06
WO2019069230A1 (en) 2019-04-11
CA3078163A1 (en) 2019-04-11
ZA202002292B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
PH12017500493A1 (en) Combination therapy
MX2018005588A (es) Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.
GB2541571A (en) Pharmaceutical compositions
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
MX2019002190A (es) Uso de pridopidina para tratar distonías.
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
EA201691567A1 (ru) Способы лечения легких травм головного мозга
SG11202108488SA (en) Istaroxime-containing intravenous formulation for the treatment of acute heart failure (ahf)
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX381311B (es) Método para el tratamiento de prurito y/o comezón.
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
IL280243A (en) Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure
TW201613639A (en) Methods for treating cardiovascular diseases
EA202193276A1 (ru) Способы лечения холангиокарциномы
WO2015142865A3 (en) Metakaryocidal treatments
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms